In vivo gene therapy of type I diabetic mellitus using a cationic emulsion containing an Epstein Barr Virus (EBV) based plasmid vector

Journal of Controlled Release : Official Journal of the Controlled Release Society
Hyuk Sang YooSeo Young Jeong

Abstract

A cationic emulsion containing an insulin expression plasmid was prepared for the treatment of type 1 diabetic mellitus (DM) in vivo. A rat proinsulin-1 gene was inserted to EBV-based plasmid vectors containing CAG promoter. Cationic emulsion composed of DOTAP and squalene was complexed with the plasmid DNA. An intravenous injection of cationic emulsion containing proinsulin gene decreased blood glucose levels for 7 days within normal range. The cationic emulsion exerted more profound effect on blood glucose levels compared to naked DNA. RT-PCR results confirmed that the proinsulin was expressed in several organs containing liver, lung, spleen, and kidney. The refractory response was invoked by multiple injections of naked DNA or cationic emulsion/DNA complex, which was later proven to be an immune response against expressed proinsulin. Therefore, the cationic emulsion showed a promising result as a novel insulin gene therapy vehicle by decreasing blood glucose level for a month.

References

Jan 26, 1989·Nature·P L Felgner, G M Ringold
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·T M KolodkaS L Woo
Sep 1, 1994·Diabetologia·A Lernmark
Nov 24, 1999·Human Gene Therapy·A M AbaiK M Barnhart
Feb 19, 2000·Gene Therapy·S Li, L Huang
Nov 18, 2000·Gene Therapy·P M Thulé, J M Liu
Apr 11, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·H ChungS Y Jeong
Jan 1, 2003·Veterinary Immunology and Immunopathology·Lucy J DavisonBrian Catchpole
May 10, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·H TeixeiraP Couvreur
Oct 11, 2003·Biochemical and Biophysical Research Communications·Kakei YasutomiOsam Mazda
Jul 13, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hyuk Sang YooSeo Young Jeong

❮ Previous
Next ❯

Citations

May 25, 2013·International Journal of Pharmaceutics·Mayurkumar Kalariya, Mansoor M Amiji
Apr 4, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Seok Min KwonSeo Young Jeong
Sep 4, 2014·BioMed Research International·Josune TorrecillaAna del Pozo-Rodríguez
Nov 15, 2014·Langmuir : the ACS Journal of Surfaces and Colloids·Iolanda FotticchiaConcetta Giancola
Jan 12, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Yu WangYanzhi Song

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.